RxDoctor Payments Data

Jonathan Winner, DO

Family Medicine · Celina, OHNPI 1962639732

Payments from drug & device makers

$430in general payments, 2019–2025

Across 29 payments — averaging $14.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$108
  • Novo Nordisk$84
  • AbbVie$58
  • Lilly USA, LLC$57
  • Boehringer Ingelheim$29
  • GSK$29
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$430100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca7$108
Novo Nordisk6$84
AbbVie4$58
Lilly USA, LLC4$57
Boehringer Ingelheim2$29
GSK2$29
Novartis1$19
Amgen1$18
Pfizer1$16
Abbott1$12

How this compares

$430 in reported general payments places this provider in the 50th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$175,184
Medicare patients
533
Services billed
3,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$55,160
RybelsusSemaglutide21$52,316
JardianceEmpagliflozin33$51,271
FarxigaDapagliflozin Propanediol50$42,269
XareltoRivaroxaban39$37,956
MounjaroTirzepatide35$37,302
TrulicityDulaglutide23$36,509
EliquisApixaban47$36,286
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$34,676
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog53$32,714
ShingrixVaricella-Zoster Ge/As01b/Pf129$28,895
AbrysvoRsv Vacc, Pref A And Pref B/Pf72$23,190
Tresiba Flextouch U-200Insulin Degludec17$13,420
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$11,023
TradjentaLinagliptin11$10,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$84$107,47560 claims
Lilly USA, LLCMounjaro, Trulicity$57$73,81158 claims
GSKTrelegy Ellipta, Shingrix, Incruse Ellipta$29$71,047187 claims
Boehringer IngelheimJardiance, Tradjenta$29$61,69344 claims
PfizerEliquis, Abrysvo$16$59,476119 claims
AstraZenecaFarxiga, Brilinta$108$51,88664 claims
AbbVieRestasis, Lumigan$58$11,89739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Celina

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →